Vedanta, PureTech’s microbiome startup, to cut staff after study setback
The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target of Vedanta and other companies like it.
Previous Post
Easing Pharmacist Burnout: How Upskilling Technicians to Administer Vaccines Can Transform Pharmacies
Next Post
Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago